Meiji Yasuda Asset Management Co Ltd. Grows Stock Holdings in Zoetis Inc. $ZTS

Posted by Francis Steltz on May 23rd, 2026

Meiji Yasuda Asset Management Co Ltd. grew its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 19.4% during the 4th quarter, Holdings Channel reports. The fund owned 40,275 shares of the company’s stock after purchasing an additional 6,532 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Zoetis were worth $5,067,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after acquiring an additional 550,859 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Zoetis by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock valued at $620,595,000 after acquiring an additional 496,320 shares during the last quarter. Finally, Fundsmith LLP boosted its holdings in shares of Zoetis by 25.3% in the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock valued at $528,966,000 after acquiring an additional 730,300 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ZTS shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. UBS Group decreased their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, Bank of America boosted their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $133.92.

Check Out Our Latest Analysis on Zoetis

Zoetis Stock Performance

NYSE:ZTS opened at $81.26 on Friday. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The company has a fifty day moving average of $108.11 and a two-hundred day moving average of $118.65. The stock has a market capitalization of $34.06 billion, a PE ratio of 13.48, a P/E/G ratio of 1.31 and a beta of 0.87. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23.

Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.6%. Zoetis’s dividend payout ratio is currently 35.16%.

About Zoetis

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.